ABC |
ATP-binding cassette transporter |
AIDS |
Acquired immunodeficiency syndrome |
AML |
Acute myeloid leukemia |
AP-1 |
Activator protein 1 |
Ara -C |
Cytarabine |
Ara-CMP |
Ara-C monophosphate |
Ara-CTP |
Ara-C triphosphate |
AZT |
Azidothymidine |
BM |
Bone marrow |
BMMNC |
Bone marrow mononuclear cells |
CDK |
Cyclin-dependent kinases |
CIA |
Clofarabine |
CLL |
Chronic lymphocytic leukemia |
CML |
Chronic myeloid leukemia |
CR |
Complete remission |
CREB |
cAMP Response Element Binding protein |
CSC |
Cancer stem cell |
dCK |
Enzyme deoxycytidine kinase |
dCMP |
Enzyme deoxycytidine monophosphate kinase |
DNA |
Deoxyribonucleic acid |
DNSP |
De novo synthesis pathway |
ELN |
European LeukemiaNet |
ERK |
Extracellular signal-regulated kinases |
EZH2 |
Enhancer of Zeste Homolog 2 |
FAB |
French-American-British Association |
FDA |
Food and drug administration |
FIA |
Fludarabine |
FLAG |
Fludarabine, cytarabine and filgrastim |
FLAG-IDA |
Fludarabine, cytarabine and filgrastim plus idarubicin |
FTI |
Farnesyl transferase inhibitor |
HCT |
Hematopoietic cell transplantation |
hENT1 |
Human balancing nucleoside transporter 1 |
HIV |
Human immunodeficiency virus |
HU |
Hydroxyurea |
JNK |
c-Jun N-terminal protein kinases |
KDM6A |
Lysine demethylase 6A |
LSC |
Leukemia stem cell |
MAPK |
Mitogen-activated protein kinase |
MDR |
Resistance multidrug |
Mnks |
MAPK-interacting kinases |
MOC |
Mechanisms of chemoresistance |
NDPK |
Nucleoside diphosphate kinase enzyme |
NF-κB |
Nuclear factor kappa light chain enhancer of activated B cells |
NSP |
Novo nucleotide synthesis |
OXPHOS |
Oxidative phosphorylation |
R/R |
Relapse and refractory disease |
RAS |
Rat sarcoma |
RNR |
Enzyme ribonucleotide diphosphate reductase |
ROS |
Reactive oxygen species |
SAMHD1 |
SAM and HD domain containing deoxynucleoside triphosphate triphosphohydrolase 1 |
shRNA |
Short hairpin RNA |
TCA |
Tricarboxylic acid cycle |
VEGF |
Vascular endothelial growth factor |
WHO |
World Health Organization |